The Cochrane Dementia and Cognitive Improvement Group produces systematic reviews within the following scope:
Prevention, treatment, and management of acute or chronic acquired cognitive impairments, their manifestations and complications, and the care of people affected. Our remit includes both global cognitive impairment and focal cognitive impairments occurring in the context of brain disease such as Alzheimer's disease, vascular dementia, fronto-temporal dementias including Pick's disease, dementia with Lewy bodies and the spongiform encephalopathies. It also extends to delirium, and to non-specific and age-associated cognitive impairments. We are concerned, in collaboration with other relevant Cochrane Groups, with cognitive impairment occurring as a complication of diseases such as diabetes, stroke and hypertension. Dementia with Parkinson's disease and in HIV disease are usually dealt with by the primary disease groups.
Single and complex interventions of all kinds are reviewed, including pharmacological, psychological, environmental, organizational, and alternative or complementary. All relevant outcomes are considered including changes in cognitive function, behaviour, activities of dailyliving, global clinical impression, dependency, carer burden, quality oflife, use of resources, survival and institutionalization. Where suitable data are available, cost-effectiveness comparisons will be included in reviews.
We are also concerned with cognitive enhancement in healthy adults, including so-called 'smart drugs'.
In addition to our intervention reviews, we currently have a portfolio of Diagnostic Test Accuracy protocols and reviews, covering both biomarker and neuropsychological tests.